FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to anti-CD19 antibodies, and can be used in medicine for treating a malignant tumour expressing CD19. Disclosed is a scFv peptide having specificity of binding to human CD19, containing the amino acid sequence of the variable region of the heavy chain SEQ ID NO: 7 and the amino acid sequence of the light chain variable region SEQ ID NO: 19. Based on said scFv peptide, multispecific antibody-like proteins having binding specificity with CD19, αEGFR, αPD-L1, α4-1BB, αHER3 and αCD3a of a human, as well as multispecific monoclonal antibodies having binding specificity to human CD19, and antibody-drug conjugates.
EFFECT: invention enables to obtain humanized antibodies specific for human CD19, having high stability and a lower risk of immunogenicity compared to the mouse antibody BU12.
30 cl, 11 dwg, 6 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MANAGEMENT, NAVIGATION AND CONTROL PROTEINS AND METHOD OF THEIR OBTAINING AND USE | 2019 |
|
RU2811457C2 |
| CELL | 2015 |
|
RU2768019C2 |
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| ANTIBODIES TO CHIMERIC ANTIGEN RECEPTORS DERIVED FROM 4G7 | 2020 |
|
RU2826051C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| METHODS OF PRODUCING AND USING GUIDE AND NAVIGATION CONTROL PROTEINS | 2019 |
|
RU2824896C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
